1. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
- Author
-
de Andrade DP, Lima JP, Lima AD, Sasse AD, and dos Santos LV
- Subjects
- Bevacizumab, Fluorouracil therapeutic use, Humans, Leucovorin therapeutic use, Male, Middle Aged, Organoplatinum Compounds therapeutic use, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor metabolism, Carcinoembryonic Antigen metabolism, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology
- Abstract
Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of the mFOLFOX6 regimen plus bevacizumab. Initially he had an increase in CEA after which the level reduced, suggesting the occurrence of a CEA flare. The patient experienced a good response to therapy. In recent literature, CEA flare was identified as a good predictor of response to first-line chemotherapy.
- Published
- 2011
- Full Text
- View/download PDF